How CJC-1295 No-DAC Affects IGF-1

CJC-1295 no-DAC raises IGF-1 through GHRH receptor-mediated priming of pituitary somatotrophs:

1. GHRH receptor agonism: CJC-1295 no-DAC is a stabilised 29-amino-acid analog of growth hormone-releasing hormone (GHRH 1-29). It binds the GHRH receptor on somatotroph cells in the anterior pituitary, priming them to release stored GH in response to a concurrent trigger signal.
2. Short half-life preserves pulsatile pattern: With a plasma half-life of approximately 30 minutes (vs. 8-9 days for DAC-modified CJC-1295), the no-DAC form produces a discrete GH pulse that resolves within 2-3 hours. This preserves the pulsatile GH secretion pattern that is physiologically important for liver IGF-1 synthesis and avoids the blunted pituitary feedback that occurs with sustained GH stimulation.
3. Synergy with GHRPs (particularly ipamorelin): GHRH analogs and GHRPs (ghrelin receptor agonists) act on different receptors and produce synergistic GH release when combined. Ipamorelin triggers the ghrelin receptor to release GH, while CJC-1295 no-DAC simultaneously amplifies the size of that pulse. The combined pulse is substantially larger than either compound alone.
4. Hepatic IGF-1 synthesis: Each amplified GH pulse drives hepatic IGF-1 synthesis. Because pulses are discrete and separated by recovery intervals, the liver's IGF-1 response accumulates without the sustained IGF-1 suppression of negative feedback that eventually limits continuous GH stimulation.

Standard dose (100 mcg SC, 1-3 times daily), CJC-1295 no-DAC alone:

• IGF-1 increases approximately 15-30% above baseline with monotherapy
• Teichman et al. (2006, PMID 16352683) characterised CJC-1295 (with DAC at higher doses) producing 1.5-3x IGF-1 elevation sustained for 9-11 days; the no-DAC form at typical bodybuilding doses produces a more modest and transient signal

Combined with ipamorelin (100 mcg CJC + 200-300 mcg ipamorelin, per injection):

• IGF-1 increases 20-60% above baseline in practice reports
• The amplified GH pulse from the combination exceeds either compound alone, approaching the IGF-1 elevation of MK-677 at 25 mg/day without the sustained GH and associated insulin resistance

Timeline: IGF-1 begins rising within 1-2 weeks of consistent dosing and reaches a new steady state by 3-4 weeks. Because of the pulsatile nature, total daily IGF-1 AUC (area under the curve) is lower than with oral GH secretagogues despite a comparable peak.

Baseline: Obtain IGF-1 before starting. Document age-matched reference range. Also obtain fasting glucose and HbA1c.

During use:

• IGF-1 at 4 weeks (to confirm target range is achieved without excess)
• Repeat IGF-1 every 3 months on an ongoing protocol
• Fasting glucose quarterly, particularly if stacking with other GH peptides (MK-677) or AAS that independently stress insulin sensitivity
• No prolactin, cortisol, or LH/FSH monitoring required; CJC-1295 no-DAC does not affect these axes

Target IGF-1 range: Most bodybuilding users aim for IGF-1 in the upper quartile of the age-matched reference range (approximately 200-350 ng/mL for adults under 40), not above the range ceiling.

Optimising the IGF-1 response:

• Inject in a fasted state or at least 2 hours after eating; dietary fats blunt pituitary GH response
• Pre-bed dosing aligns with the natural nocturnal GH surge for a synergistic pulse
• Always pair with a GHRP (ipamorelin is the cleanest option) to maximise pulse amplitude; GHRH analogs alone produce a submaximal pulse without a concurrent trigger signal
• Use bacteriostatic water for reconstitution and store at 4C after reconstituting; denatured peptide produces no response

If IGF-1 response is poor:

• Confirm fasted injection timing; this is the single most common reason for blunted response
• Verify product integrity and storage conditions
• Increase injection frequency from once to twice or three times daily
• Add or increase the ipamorelin component if not already combined